文献速递眼底病与葡萄膜炎

年龄相关性黄斑变性玻璃体腔注射后感染性与非感染性眼内炎的发生率与结局

Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.
PubMed 文献 · Ophthalmology · 2017-08-08

FRB登记研究分析2006至2016年接受抗VEGF治疗的初治新生血管性年龄相关性黄斑变性眼,感染性眼内炎发生率为每4897次注射1例(0.020%),非感染性眼内炎为每8013次注射1例(0.012%);感染性眼内炎风险不随注射次数增加,贝伐珠单抗的非感染性眼内炎发生率高于雷珠单抗和阿柏西普。

要点

  • 感染性眼内炎发生率为每4897次注射1例(0.020%,95%CI 0.012-0.032),不同抗VEGF药物间无差异(P=0.896)。
  • 非感染性眼内炎发生率为每8013次注射1例(0.012%,95%CI 0.006-0.022),贝伐珠单抗0.081%高于雷珠单抗0.005%(P=0.005)和阿柏西普0/23425(P=0.016)。
  • 感染性眼内炎后12个月53%眼视力在±2行内,31%眼视力下降超过2行;非感染性眼内炎分别为75%和25%。

核心结论

  • 玻璃体腔注射后感染性和非感染性眼内炎发生率均低,且风险不随每次连续注射而增加。
  • 贝伐珠单抗的非感染性眼内炎发生率高于雷珠单抗或阿柏西普。
  • 约四分之三的感染性眼内炎眼和三分之二的非感染性眼内炎眼视力保持在眼内炎前10个字母以内。

研究设计与样本

  • 前瞻性设计的数据库研究,纳入FRB登记中2006年1月1日至2016年11月30日期间开始抗VEGF治疗的初治新生血管性年龄相关性黄斑变性眼。
  • 采用Cox比例风险模型计算眼内炎累积率和生存曲线,用局部加权散点平滑曲线展示视力。

主要发现

  • 感染性眼内炎发生于88150次注射中的18次(每4897次注射1例[0.020%];95%CI 0.012-0.032),不同抗VEGF药物类型间无差异(P=0.896)。
  • 每例患者感染性眼内炎累积率在10、20、30、40、50、60次注射后分别为0.055%、0.183%、0.360%、0.360%、0.555%、0.843%,但感染性眼内炎的「风险」不随每次连续注射增加(P=0.202)。
  • 非感染性眼内炎发生于88150次注射中的11次(每8013次注射1例[0.012%];95%CI 0.006-0.022),每例患者累积率在10和20次注射后分别为0.087%和0.228%,之后至60次注射保持稳定。
  • 非感染性眼内炎发生率贝伐珠单抗为8/9931(0.081%),高于雷珠单抗3/54776(0.005%;P=0.005)和阿柏西普0/23425(P=0.016),雷珠单抗与阿柏西普间无差异(P=1.0)。
  • 感染性和非感染性眼内炎后12个月视力在眼内炎前±2行内的眼分别占53%和75%,视力下降超过2行的眼分别占31%和25%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the incidence, cumulative rate, and long-term outcomes of infectious and noninfectious endophthalmitis after intravitreal injections (IVTs) of anti-vascular endothelial growth factor (VEGF) agents. DESIGN: Database study, prospectively designed. PARTICIPANTS: Treatment-naïve eyes with neovascular age-related macular degeneration (nAMD) tracked by the Fight Retinal Blindness! (FRB!) registry that commenced anti-VEGF therapy between January 1, 2006, and November 30, 2016. METHODS: Cumulative rate of endophthalmitis and survival curves were measured using Cox-proportional hazards models. Locally weighted scatterplot smoothing curves were used to display visual acuity (VA). MAIN OUTCOME MEASURES: Incidence and cumulative rate of endophthalmitis, and change in VA 12 months after endophthalmitis. RESULTS: Infectious endophthalmitis developed in 18 of 88 150 injections (1/4897 injections [0.020%]; 95% confidence interval [CI], 0.012-0.032) with no difference found between types of anti-VEGF medications (P = 0.896). The cumulative rate of infectious endophthalmitis per patient was 0.055%, 0.183%, 0.360%, 0.360%, 0.555%, and 0.843% after 10, 20, 30, 40, 50, and 60 IVTs, respectively. However, the "risk" of infectious endophthalmitis did not increase with each successive injection (P = 0.202). Noninfectious endophthalmitis developed in 11 of 88 150 injections (1/8013 injections [0.012%]; 95% CI, 0.006-0.022). The cumulative rate of noninfectious endophthalmitis per patient was 0.087% and 0.228% after 10 and 20 IVTs, respectively, and then remained stable up to 60 IVTs. The incidence of noninfectious endophthalmitis was higher for bevacizumab (8/9931, 0.081%) compared with ranibizumab (3/54 776, 0.005%; P = 0.005) and aflibercept (0/23 425; P = 0.016), and no differences were observed between ranibizumab and aflibercept (P = 1.0). The 12-month VA in infectious and noninfectious endophthalmitis was within ±2 lines of before endophthalmitis in 53% and 75% of eyes, respectively; a loss >2 lines was observed in 31% and 25% of eyes, respectively. CONCLUSIONS: The incidences of infectious and noninfectious endophthalmitis after IVT were low, and the risk did not increase with each successive injection. We found higher rates of noninfectious endophthalmitis with bevacizumab compared with ranibizumab or aflibercept. Three quarters of cases with infectious and two thirds of cases with noninfectious endophthalmitis retained vision within 10 letters of the pre-endophthalmitis level.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Daien V, Nguyen V, Essex RW, et al. Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration. Ophthalmology. 2017. PMID: 28801117. doi:10.1016/j.ophtha.2017.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。